KIMco to Hold 'Global New Drug Development Strategy Workshop' with Syneos Health

From Candidate Substance Discovery to Phase 3 Clinical Trials
Presenting Global New Drug Development Strategies

[Asia Economy Reporter Lee Gwanju] The Korea Innovative Medicines Consortium (KIMco) announced on the 1st that it will hold a "Global New Drug Development Strategy Workshop" with Syneos Health, a company providing integrated solutions for the pharmaceutical and bio industries, on the 11th of next month at the Grand InterContinental Seoul Parnas in Gangnam-gu, Seoul.

This workshop, aimed at executives and stakeholders in R&D, clinical, and business development departments of domestic pharmaceutical and bio companies, will present strategies for each stage of global new drug development from new drug candidate discovery to late-stage clinical trials and commercialization, and explore the possibility of developing global blockbuster new drugs through sharing success stories.

The event will consist of presentations including ▲ Candidate discovery and development strategies with commercialization in mind (Ken Lee, Senior Vice President, Asia Pacific, Syneos Health) ▲ Proof of Concept (POC) confirmation and early clinical development acceleration strategies (Nicholas Kenny, Chief Scientific Officer, Syneos Health) ▲ Cases for Phase 3 success (Stephanie Gonzalez, Vice President, Biotech Business Unit, Syneos Health; Suma Ramadas, Senior Vice President, Medical Affairs, Syneos Health) ▲ Value creation and partnership ecosystem building for late-stage clinical trials (James Mann, Head of Consulting, Syneos Health; Stephanie Gonzalez, Vice President, Biotech Business Unit, Syneos Health) ▲ Recent investment trends and strategies in the pharmaceutical and bio industry (Nicholas Kenny, Chief Scientific Officer, Syneos Health).

After the presentations, Moon Hanlim, CEO of Medirama, will chair a panel discussion on the topic "Challenges for the Success of Global New Drug Development by Domestic Pharmaceutical and Bio Companies." Panelists will include Lee Hyunggi, Professor of Clinical Pharmacology at Seoul National University Hospital and a global new drug development advisory member of KIMco, and Park Gihwan, Professor at KAIST.

Huh Kyunghwa, CEO of KIMco, said, "It is now time for the domestic pharmaceutical and bio industry to challenge the full process of global new drug development beyond the achievements of global technology exports," adding, "We expect this workshop to serve as a stepping stone for domestic pharmaceutical and bio companies' global new drug development."

Lee Sora, CEO of Syneos Health, said, "Korea is a country attracting attention in the global market due to active new drug development activities, and I am pleased to share Syneos Health’s accumulated know-how and global experience in new drug development at this time," adding, "Through this workshop, by expanding perspectives with integrated strategies covering the entire cycle, we will contribute to increasing the success rate of global new drug development by domestic pharmaceutical and bio companies."

This content was produced with the assistance of AI translation services.